European Pharmaceutical Manufacturer examines some of the biggest trends that have taken place throughout 2019.
Pharma Trends
Mergers & Acquisitions
The beginning of 2019 was marked with by a string of large-scale acquisitions which would be indicative of the state of pharma and where the industry was headed. In January, both Bristol-Myers Squibb and Eli Lilly’s expanded their treatment portfolios with acquisitions that were worth $74 billion and $8 billion respectively.
Soon after, in February and April, the industry saw Catalent and Roche move into the gene therapy market with their acquisitions of Paragon Bioservices and Spark Therapeutics.